L3 diabetes type 1:
	- diabetes mellitus physiology:
		- 70-99mg/dl nromal range
		- post-prandial < 140mg/dl
		- dx:
			- FPG >= 126 mg/dl (fast >= 8h)
			- 2h PG >= 200 mg/dl OGTT
			- A1C >= 6.5%
			- hyperglycemia symptoms + random PG >= 200 mg/dl

		- types:
			- type 1: destruction of β-cells
			- type 2: loss of β-cell insulin secretion + insulin resistance
			- gestational diabetes: 2nd or 3rd trimester dx
			- other: monogenic diabetes syndromes, exocrine pancrease diseases, drug induced

	- diabetes type 1:
		- symptoms:
			- polydipsia
			- polyphagia
			- polyuria
			- nocturnal enuersis
			- weight loss
			- irritable
			- emesis + lethargy
		- tx:
			- always insulin!
		- epidiomiology:
			- onset: 5-7 yo and after puberty
				- 9 mo to 90 yo
			- increasing incidence
			- M:F = 1.32
			- incidence: 1:300 normal, 1:20 if 1st degree relative
		
		- risks:
			- HLA DR3/4
			- FH of autoimmunity
			- triggers: maybe viruses, nutrition, hygiene
		- pathogenesis:
			- autoreactive T cells
			- normal iselt -> insulitis (autoantibodies present) -> β-cell destruction (over diabetes)
		- dx:
			- antibodies:
				- GAD65: glutamic acid decarboxylase
				- ICA: islet cell antibodies
				- IAA: insulin autoantibodies
				- zinc transporter
		- tx:
			- prevention: teplizumab (anti-CD3) delays onset
			- 
		- course:
			- precipitating event -> normal insulin -> insulin loss/normal glucose
			- C-peptide present (overt diabetes) -> no C-peptide

	- diabetic ketoacidosis:
		- symptoms:
			- emesis + lethargy
		- physical exam:
			- tired
			- sunken eyes
			- dry mucous membranes
			- tachycardia
			- increased cap refill
			- cold extremities
		- signs:
			- kussmaul respirations
			- hyperglycemia
			- acidosis
			- acetone breath
			- ketones + glucose in urine
		- tx:
			- IV fluids
			- insulin drip

	- insulin pathways:
		- released from β-cells
		- stimulates glucose usage/uptake
			- uptake mainly in skeletal muscles
			- insulin binds insulrin receptor -> GLUT4 membrane fusion

	- insulin + blood sugar management:
		- types:
			- rapid (2h): lispro, aspart, glulisine
			- short (5h): regular
			- intermediate (12): nph
			- long acting: glargine, detemir

		- paradigm:
			- bolus + basal
			- basal:
				- always need insulin, constant dose
				- suppresses gluconeogenesis at night + between meals
			- bolus:
				- 15 mins preprandial
				- needed for all carbs
				- dose ~ f(PG, carb load)
		- limits:
			- subq not rapid enough for SUGARY stuff
			- insulin irreversible -> hypoglycemic risk
			- expensive

		- check PG:
			- before meals, bed, driving
			- pre/post exercise
			- 6-10x per day

		- pumps:
			- microdoses (.025 unitsq)